Skip to content Skip to footer
Subscribe Now
NEWS

Combotope Therapeutics and Boehringer Ingelheim Collaborate on Next-Generation Cancer Antibody Therapies

Shots: BI has entered into a strategic research collaboration with Combotope to leverage its SMART-Phage platform to produce highly tumor-selective antibodies for next-generation cancer therapies Combotope will discover tumor-selective, high-affinity antibodies against multiple BI oncology targets, while BI will hold global development & commercialization rights, and lead further R&D, manufacturing, & commercialization activities As per…
June 24, 2026

Read more

NEWS

Abbisko Therapeutics Inks ~$1.9B Multi-Target R&D Deal with Eli Lilly

Shots: Abbisko Therapeutics has entered into a strategic research collaboration & license agreement with Eli Lilly to discover & develop novel therapeutics across multiple targets Abbisko will leverage its early-stage drug discovery platform, R&D ecosystem, & development expertise to conduct discovery & early-stage development of novel therapeutics against disease targets selected by Lilly As per…
June 24, 2026

Read more

NEWS

Nuvectis Expands Pipeline with ~ $1.46B Ex-China Licensing Deal for Two Late-Stage Assets from Haisco

Shots: Nuvectis has licensed exclusive ex-China rights to NXP100 (HSK39297; QD, PO), a Complement Factor B inhibitor, & NXP200 (HSK42360), a brain-penetrant paradox-breaker BRAF inhibitor from Haisco, transforming the company into a late-stage development player  As per the deal, Haisco will receive ~$40M in upfront & near-term payments, plus up to $1.421B in development,…
June 23, 2026

Read more

NEWS

TrueLab Inks ~$985M Deal with Bionyra to Advance Two Immune-Mediated Inflammatory Disease Therapies

Shots: TrueLab has granted Bionyra exclusive worldwide rights, excl. Greater China, to research, develop, manufacture, & commercialize TL-001, an anti-TL1A monoclonal antibody, & TL-003, a TL1A × IL-23p19 bispecific antibody As per the deal, TrueLab will receive ~$985M in total consideration, incl. an upfront payment as well as development, regulatory, & commercial milestone payments, with tiered…
June 23, 2026

Read more

NEWS

Murj Expands Commercial Operations Across Australia and New Zealand for Cardiac Device Management Solutions

Shots: Murj announced the commercial launch of its cardiac device management platform in Australia and expanded availability in New Zealand, following its participation at the CSANZ/HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne The expansion enables healthcare providers across the region to access Murj’s cloud-native solutions for cardiac implantable electronic device (CIED)…
June 22, 2026

Read more

NEWS

Takeda Partners with Boltz to Advance AI-Driven Drug Discovery

Shots: Boltz has partnered with Takeda to deploy its biomolecular AI platform across Takeda’s research organization, providing discovery teams access to proprietary foundation models, incl. BoltzMol-1 & BoltzProt-1, to accelerate AI-driven drug discovery The platform is designed to support in-silico molecular design, enabling structure prediction, affinity estimation, and generative design to enhance AI-driven drug discovery…
June 19, 2026

Read more

NEWS

Voro Therapeutics and Alloy Therapeutics Partner on Next-Generation T-Cell Engagers

Shots: Voro Therapeutics & Alloy Therapeutics have entered into a strategic research collaboration to discover and develop next-generation masked T-cell engager (TCE) therapies Partnership will combine Voro’s PrimeBody platform with Alloy’s optimized CD3 antibodies & multispecific engineering capabilities to develop novel immunotherapies designed to selectively activate immune responses within tumors PrimeBody is designed to unlock difficult-to-target…
June 19, 2026

Read more

NEWS

LabGenius Therapeutics and LG Chem Collaborate to Develop an AI/ML-Designed Tumour-Targeting Antibody

Shots: LabGenius has entered into a multi-year research collaboration, option & licensing agreement with LG Chem to identify next-generation multispecific antibodies for difficult-to-treat cancers, leveraging LabGenius’ AI/ML-driven antibody discovery platform, EVA As per the licensing deal, LabGenius will lead preclinical research, incl. in vitro efficacy studies, after which LG Chem will conduct further preclinical development, incl.…
June 18, 2026

Read more

NEWS

Biogen to Acquire RayThera for ~$1B

Shots: Biogen has entered into a definitive agreement to acquire RayThera, expanding its immunology pipeline As per the deal, Biogen will acquire RayThera for ~$1B, incl. an upfront payment & clinical and regulatory milestone payments; closing is expected in Q3’26 Following closing, Biogen will lead development, manufacturing & global commercialization of RayThera’s assets, incl. the…
June 18, 2026

Read more

Load more